In the last three months, Ginkgo Bioworks' (NYSE: DNA) shares fell by 50%. To the enterprising investor, such a decline by the Boston-based biotech specialist isn't necessarily a sign of disaster, and ...

Ginkgo Bioworks Holdings, Inc. (DNA) ended the recent trading session at $15.12, demonstrating a -4.49% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a ...

In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $12.74, marking a -4.85% move from the previous day. This change lagged the S&P 500's daily gain of 0.23%. Meanwhile, the ...

It has been difficult to be a shareholder of Ginkgo Bioworks (NYSE: DNA) over the past year. The stock has collapsed about 72% from its peak last summer. The company's cell engineering foundry is an ...

Cathie Wood-led Ark Invest on Friday snapped up more shares in Ginkgo Bioworks Holdings Inc DNA on the dip. The popular money manager’s investment firm snapped up 1.53 million shares — estimated to be ...

Cathie Wood's Ark Invest bought the dip in Ginkgo Bioworks after the stock tumbled as much as 24%. Scorpion Capital slammed Ginkgo's business model, alleging it was a "Frankenstein mash-up of frauds." ...

Cathie Wood-led Ark Invest on Wednesday snapped up shares in Ginkgo Bioworks Holdings Inc (NYSE:DNA) on the day the synthetic biology company stock was hit hard by two back-to-back short-seller ...

Ginkgo Bioworks is still struggling with operating efficiency. Management is signaling that its processes may be streamlined. This isn't the right dip-buying opportunity for everyone. Is that the case ...

Ginkgo Bioworks Holdings, Inc. (DNA) closed at $12.32 in the latest trading session, marking a -0.48% move from the prior day. The stock's change was less than the S&P 500's daily loss of 0.27%.